MedImmune chief, R&D head leave posts

MedImmune chief executive David Mott and the head of research and development, James Young, have resigned, just a year after AstraZeneca PLC's acquisition of the biotech firm. The unexpected departure of Mott, which takes effect at the end of July, and Young, who left his post earlier this month, deals another blow to AstraZeneca and reflects the challenges drugmakers face in keeping prime biotech talent on staff.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR